Literature DB >> 21566922

The receptor for EGF and its ligands - expression, prognostic value and target for therapy in cancer (review).

H Modjtahedi, C Dean.   

Abstract

The results of recent studies suggest that overexpression of the EGF receptor accompanied by production of its ligands is an important characteristic of human squamous cell carcinomas. The EGF receptor which transmits the growth promoting or inhibitory effects of epidermal growth factor (EGF), transforming growth factor alpha (TGFalpha) and amphiregulin is a member of the type I family of growth factor receptors which possess tyrosine kinase activity. In this review we a) discuss the role played by this receptor and its ligands in the transformation of normal cells, b) analyze the evidence for expression of the receptor and its ligands as prognostic markers in cancer patients and c) indicate ways that the overexpressed EGF-receptor system on human malignant cells can be targeted for therapeutic application.

Entities:  

Year:  1994        PMID: 21566922     DOI: 10.3892/ijo.4.2.277

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  27 in total

1.  Dynamic changes of serum protein in rats with acute intoxication of Chinese cobra snake venom by proteomic analysis.

Authors:  Hui Yan; Ping Xiang; Jingshuo Zhang; Liqi Xie; Min Shen
Journal:  Forensic Sci Res       Date:  2017-12-21

2.  Evaluation of systemically administered radiolabeled epidermal growth factor as a brain tumor targeting agent.

Authors:  W Yang; R F Barth; R Leveille; D M Adams; M Ciesielski; R A Fenstermaker; J Capala
Journal:  J Neurooncol       Date:  2001-10       Impact factor: 4.130

3.  Molecular characterization of head and neck cancer: how close to personalized targeted therapy?

Authors:  Maria J Worsham; Haythem Ali; Jadranka Dragovic; Vanessa P Schweitzer
Journal:  Mol Diagn Ther       Date:  2012-08-01       Impact factor: 4.074

4.  Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice.

Authors:  M W Kunkel; K E Hook; C T Howard; S Przybranowski; B J Roberts; W L Elliott; W R Leopold
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 5.  Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment.

Authors:  R Radinsky
Journal:  Cancer Metastasis Rev       Date:  1995-12       Impact factor: 9.264

6.  Delivery of optical contrast agents using Triton-X100, part 2: enhanced mucosal permeation for the detection of cancer biomarkers.

Authors:  Anne L van de Ven; Karen Adler-Storthz; Rebecca Richards-Kortum
Journal:  J Biomed Opt       Date:  2009 Mar-Apr       Impact factor: 3.170

7.  Targeting doxorubicin to epidermal growth factor receptors by site-specific conjugation of C225 to poly(L-glutamic acid) through a polyethylene glycol spacer.

Authors:  Javier Vega; Shi Ke; Zhen Fan; Sidney Wallace; Chusilp Charsangavej; Chun Li
Journal:  Pharm Res       Date:  2003-05       Impact factor: 4.200

8.  Epigenetic modulation of signal transduction pathways in HPV-associated HNSCC.

Authors:  Maria J Worsham; Kang Mei Chen; Tamer Ghanem; Josena K Stephen; George Divine
Journal:  Otolaryngol Head Neck Surg       Date:  2013-06-04       Impact factor: 3.497

9.  Efficacy of an EGFR-specific peptide against EGFR-dependent cancer cell lines and tumor xenografts.

Authors:  Aarif Ahsan; Susmita G Ramanand; Ingrid L Bergin; Lilli Zhao; Christopher E Whitehead; Alnawaz Rehemtulla; Dipankar Ray; William B Pratt; Theodore S Lawrence; Mukesh K Nyati
Journal:  Neoplasia       Date:  2014-02       Impact factor: 5.715

10.  Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line.

Authors:  R Banerjee; Z Rachid; Q Qiu; J P McNamee; A M Tari; B J Jean-Claude
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.